Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $58,135 | 26 | 91.3% |
| Unspecified | $2,871 | 1 | 4.5% |
| Food and Beverage | $2,526 | 113 | 4.0% |
| Honoraria | $125.00 | 1 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Baxter Healthcare | $51,075 | 24 | $0 (2023) |
| Welch Allyn | $7,185 | 3 | $0 (2019) |
| Allergan, Inc. | $3,060 | 18 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $403.61 | 14 | $0 (2024) |
| ABBVIE INC. | $269.84 | 16 | $0 (2024) |
| Alimera Sciences, Inc. | $228.19 | 16 | $0 (2023) |
| Sun Pharmaceutical Industries Inc. | $180.76 | 5 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $152.30 | 8 | $0 (2021) |
| Alcon Vision LLC | $150.75 | 1 | $0 (2023) |
| Bausch & Lomb Americas Inc. | $142.16 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $156.12 | 7 | Astellas Pharma US Inc ($52.66) |
| 2023 | $33,867 | 37 | Baxter Healthcare ($32,990) |
| 2022 | $18,489 | 34 | Baxter Healthcare ($18,085) |
| 2021 | $386.81 | 20 | Allergan, Inc. ($89.75) |
| 2020 | $241.36 | 8 | Regeneron Pharmaceuticals, Inc. ($112.85) |
| 2019 | $6,382 | 13 | Welch Allyn ($6,210) |
| 2018 | $1,063 | 7 | Welch Allyn ($975.00) |
| 2017 | $3,073 | 15 | Allergan Inc. ($2,920) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $13.79 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.84 | General |
| Category: EYE CARE | ||||||
| 08/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Ophthalmology | ||||||
| 05/10/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $28.10 | General |
| Category: EYE CARE | ||||||
| 04/17/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $18.60 | General |
| Category: Ophthalmology | ||||||
| 03/28/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $21.13 | General |
| Category: Ophthalmology | ||||||
| 03/15/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $28.56 | General |
| Category: Ophthalmology | ||||||
| 12/08/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $3,225.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 11/29/2023 | RxSight Inc | RXSIGHT CONTACT LENS (Device), RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE | Food and Beverage | In-kind items and services | $138.55 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/15/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $4,100.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 11/03/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.07 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/03/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $1.02 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/02/2023 | Alimera Sciences, Inc. | ILUVIEN (Drug) | Food and Beverage | Cash or cash equivalent | $23.57 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/13/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $3,585.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 09/15/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $23.32 | General |
| Category: Ophthalmology | ||||||
| 09/12/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: EYE CARE | ||||||
| 09/11/2023 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Ophthalmology | ||||||
| 09/11/2023 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Ophthalmology | ||||||
| 09/08/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $2,555.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 09/02/2023 | Astellas Pharma US Inc | — | Food and Beverage | In-kind items and services | $26.18 | General |
| 08/31/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/18/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/11/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $2,770.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 07/24/2023 | Baxter Healthcare | Hillrom - RetinaVue 700 Imager (Device), Hillrom - RetinaVue Network | Consulting Fee | Cash or cash equivalent | $4,070.00 | General |
| Category: Physical Assessment, Vision | ||||||
| 06/22/2023 | Johnson & Johnson Surgical Vision, Inc. | Tecnis IOL (Device), Tecnis IOL, Tecnis IOL | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Optics | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration | Allergan Inc. | $2,871 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 2,371 | 9,659 | $1.8M | $647,765 |
| 2022 | 12 | 2,941 | 7,029 | $2.2M | $700,874 |
| 2021 | 14 | 2,820 | 6,792 | $2.6M | $806,594 |
| 2020 | 14 | 2,446 | 6,287 | $3.4M | $701,555 |
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 69 | 412 | $824,000 | $284,556 | 34.5% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 22 | 4,920 | $187,255 | $142,890 | 76.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 581 | 913 | $182,600 | $83,046 | 45.5% |
| 67028 | Injection of drug into eye | Office | 2023 | 173 | 621 | $226,100 | $53,084 | 23.5% |
| 92134 | Imaging of retina | Office | 2023 | 625 | 1,486 | $148,600 | $43,341 | 29.2% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 101 | 309 | $63,100 | $20,115 | 31.9% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 367 | 441 | $132,300 | $8,005 | 6.1% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 366 | 490 | $49,000 | $5,661 | 11.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 34 | 34 | $10,500 | $3,537 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $9,900 | $3,530 | 35.7% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 81 | 524 | $1.0M | $376,630 | 35.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 657 | 1,020 | $204,000 | $90,391 | 44.3% |
| 67028 | Injection of drug into eye | Office | 2022 | 218 | 757 | $341,100 | $63,431 | 18.6% |
| 92134 | Imaging of retina | Office | 2022 | 727 | 1,684 | $168,400 | $48,413 | 28.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 12 | 162 | $164,430 | $35,920 | 21.8% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2022 | 12 | 960 | $36,538 | $28,645 | 78.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2022 | 134 | 374 | $37,400 | $24,380 | 65.2% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2022 | 555 | 876 | $87,600 | $10,351 | 11.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 391 | 518 | $114,200 | $9,342 | 8.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 73 | 73 | $21,900 | $6,960 | 31.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 57 | 57 | $17,100 | $5,706 | 33.4% |
| 92250 | Photography of the retina | Office | 2022 | 24 | 24 | $3,600 | $704.60 | 19.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 68 | 482 | $964,000 | $353,629 | 36.7% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2021 | 25 | 485 | $484,155 | $123,079 | 25.4% |
| J0179 | Injection, brolucizumab-dbll, 1 mg | Office | 2021 | 13 | 325 | $189,586 | $81,250 | 42.9% |
About Dr. John Lehr, MD
Dr. John Lehr, MD is a Retina Specialist healthcare provider based in Orlando, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1447211289.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Lehr, MD has received a total of $63,657 in payments from pharmaceutical and medical device companies, with $156.12 received in 2024. These payments were reported across 141 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($58,135).
As a Medicare-enrolled provider, Lehr has provided services to 10,578 Medicare beneficiaries, totaling 29,767 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Orlando, FL
- Active Since 03/31/2006
- Last Updated 09/13/2024
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1447211289
Products in Payments
- Hillrom - RetinaVue 700 Imager (Device) $51,075
- RetinaVue Network (Device) $6,335
- RetinaVue 100 Imager (Device) $850.00
- EYLEA (Biological) $441.67
- OZURDEX (Drug) $323.80
- Clareon (Device) $150.75
- XIPERE (Drug) $142.16
- BEOVU (Drug) $140.82
- RXSIGHT CONTACT LENS (Device) $138.55
- Iluvien (Drug) $113.02
- Bromsite (Drug) $100.00
- ILUVIEN (Drug) $78.55
- DURYSTA (Drug) $74.52
- CEQUA (Drug) $62.41
- VABYSMO (Drug) $62.12
- Izervay (Drug) $52.66
- Omidria (Drug) $52.54
- EYLEA HD (Biological) $50.88
- Tecnis IOL (Device) $50.56
- Syfovre (Drug) $44.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Retina Specialist Doctors in Orlando
Matthew Cunningham, Md, MD
Retina Specialist — Payments: $356,361
Samuel Houston, Md, MD
Retina Specialist — Payments: $134,791
Jaya Kumar, Md, MD
Retina Specialist — Payments: $22,212
Elia Mavrofrides, Md, MD
Retina Specialist — Payments: $13,251
Gabrielle Turski, Md Phd, MD PHD
Retina Specialist — Payments: $4,476
Dr. John Randolph, Md, MD
Retina Specialist — Payments: $2,902